Tag: Daiichi Sankyo
-
Datroway Receives FDA Approval for Advanced Triple‑Negative Breast Cancer: What This Breakthrough Means for Patients
Triple‑negative breast cancer, often shortened to TNBC, has long been one of the most challenging forms of breast cancer to treat. Unlike other breast cancer types, TNBC does not have the three common receptors that many modern treatments target. This means patients have historically had fewer options, and many have had to rely on chemotherapy